149
IRUS TotalDownloads
Altmetric
Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease
File | Description | Size | Format | |
---|---|---|---|---|
ExacRecoveryRevisionGD.docx | Accepted version | 161.29 kB | Microsoft Word | View/Open |
Title: | Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease |
Authors: | Donaldson, GC Law, M Kowlessar, B Singh, R Brill, SE Allinson, JP Wedzicha, JA |
Item Type: | Journal Article |
Abstract: | INTRODUCTION: COPD exacerbations are important and heterogeneous events, but the consequences of prolonged exacerbation recovery are unknown. METHODS: A cohort of 384 COPD patients (FEV1 % predicted 45.8 (SD 16.6) and a median exacerbation rate of 2.13 per year (IQR 1.0-3.2)) were followed for 1039 days (IQR 660-1814) between October 1995 and January 2013. Patients recorded daily worsening of respiratory symptoms and peak expiratory flow (PEF), and when stable underwent 3-monthly spirometry, and completed the St. George's Respiratory Questionnaire (SGRQ) annually. Exacerbations were diagnosed as two consecutive days with one major symptom plus another respiratory symptom. Exacerbation duration was defined as the time from onset to the day preceding two consecutive symptom-free and recovery in PEF as return to pre-exacerbation levels. RESULTS: 351 patients had 1 or more exacerbations. Patients with a longer symptom duration (mean 14.5 days) had a worse SGRQ total score (0.2 units per 1 day; p=0.040). A longer symptomatic duration was associated with a shorter interval between exacerbation recovery and onset of the next exacerbation (Hazard Ratio=1.004; p=0.013). For 257 (7.3%) exacerbations, PEF did not recover within 99 days. These exacerbations were associated with symptoms of a viral infection (cold and sore throat). Patients with these non-recovered exacerbations showed a 10.8 ml/year (p<0.001) faster decline in FEV1. CONCLUSION: Prolonged exacerbation symptomatic duration is associated with poorer health status and a greater risk of a new event. Exacerbations where lung function does not recover are associated with symptoms of viral infections and accelerated decline in FEV1. |
Issue Date: | 7-Jul-2015 |
Date of Acceptance: | 6-Jul-2015 |
URI: | http://hdl.handle.net/10044/1/25385 |
DOI: | 10.1164/rccm.201412-2269OC |
ISSN: | 1535-4970 |
Publisher: | American Thoracic Society |
Start Page: | 943 |
End Page: | 950 |
Journal / Book Title: | American Journal of Respiratory and Critical Care Medicine |
Volume: | 192 |
Issue: | 8 |
Copyright Statement: | © 2015 American Thoracic Society |
Sponsor/Funder: | Medical Research Council (MRC) Guys & St Thomas NHS Foundation Trust |
Funder's Grant Number: | G0800570/2 RCF funding from LNW CRN |
Keywords: | COPD Exacerbations Non-recovery Recovery Risk interval Science & Technology Life Sciences & Biomedicine Critical Care Medicine Respiratory System General & Internal Medicine COPD exacerbations recovery risk interval nonrecovery QUALITY-OF-LIFE COPD EXACERBATIONS RHINOVIRUS INFECTION LUNG-FUNCTION INFLAMMATORY MARKERS DECLINE HEALTH AIRWAY PHAGOCYTOSIS MOXIFLOXACIN COPD exacerbations nonrecovery recovery risk interval Aged Cohort Studies Disease Progression Female Forced Expiratory Volume Humans Longitudinal Studies Male Middle Aged Peak Expiratory Flow Rate Pharyngitis Proportional Hazards Models Prospective Studies Pulmonary Disease, Chronic Obstructive Quality of Life Recovery of Function Respiratory Tract Infections Risk Factors Time Factors Virus Diseases Vital Capacity Humans Respiratory Tract Infections Virus Diseases Pharyngitis Pulmonary Disease, Chronic Obstructive Disease Progression Vital Capacity Peak Expiratory Flow Rate Forced Expiratory Volume Proportional Hazards Models Risk Factors Cohort Studies Longitudinal Studies Prospective Studies Recovery of Function Time Factors Quality of Life Aged Middle Aged Female Male Respiratory System 11 Medical and Health Sciences |
Publication Status: | Published |
Online Publication Date: | 2015-07-07 |
Appears in Collections: | National Heart and Lung Institute Faculty of Medicine |